老年患者下呼吸道感染3种治疗方案的成本-效果分析  

Cost-Effectiveness Analysis of Three Therapeutic Schemes for Lower Respiratory Tract Infection in Elderly Patients

作　　者：陈富超[1] 方宝霞[1] 朱军[1] 于琳[1] 

机构地区：[1]湖北医药学院附属东风医院药学部,湖北十堰442008

出　　处：《中国药业》2011年第21期55-56,共2页China Pharmaceuticals

摘　　要：目的分析3种不同治疗方案对老年患者下呼吸道感染所产生的疗效及经济效果。方法将98例住院患者随机分成3组,分别给予头孢地嗪(A组)、甲磺酸帕珠沙星(B组)、哌拉西林舒巴坦(C组)治疗10 d,运用最小成本法进行经济学评价。结果 A组、B组、C组总有效率分别为85.29%,87.50%,81.25%,成本-效果比分别为14.26,13.23,17.43。结论甲磺酸帕珠沙星治疗老年患者下呼吸道感染是较佳方案。Objective To evaluate the pharmacoeconomic effects of three antibacterial drug therapies for the treatment of lower respiratory tract infection（LRTI） in elderly patients.Methods A total of 98 LRTI patients were randomized to cefodizime（group A）,pazufloxacin（group B） and piperacillin/sulbactam（group C） with a course of treatment at 10 days for each group.The cost-minimization analysis was conducted for the evaluation of the three schemes.Results The effective rate of the three groups（A,B,C） were 85.29%,87.50%,81.25%,respectively;the cost-effectiveness ratios were 14.26,13.23,17.43,respectively.Conclusion The regimen of pazufloxacin is the optimal one among the 3 groups for lower respiratory tract infection in elderly patients.

关 键 词：下呼吸道感染 抗菌药物 成本-效果分析 

分 类 号：R969.3[医药卫生—药理学] R978[医药卫生—药学]